The Healthcare Distribution Alliance (HDA) and fellow members of the National Conference of Pharmaceutical Organizations (NCPO) have requested a meeting with the Trump Administration to identify and implement specific recommendations included as part of the President’s Commission on Combating Drug Addiction and the Opioid Crisis.
The Healthcare Distribution Alliance (HDA) was named one of the Best Places to Work in Virginia by Virginia Business magazine and Best Companies Group.
Efforts to mitigate the prescription drug abuse epidemic and activities surrounding DSCSA implementation once again top the list of priorities HDA will be addressing in the year ahead, according to HDA President and CEO John M. Gray. Mr. Gray provided his perspective, along with other healthcare supply chain leaders, as part of Chain Drug Review’s annual “Pharmacy Outlook” feature, published in the January 1 issue.
HDA President and CEO John M. Gray released the following statement in response to the latest reporting by The Washington Post.
Specialty pharmaceutical distributors expect products in the autoimmune/immune and ophthalmology categories to rise in importance over the next 12 months, followed by oncology, central nervous system and inflammatory products. The findings were published in the HDA Research Foundation’s 2017 edition of Specialty Pharmaceutical Distribution: Facts, Figures and Trends.
John Parker
(703) 885-0216
Farah Simonett
(703) 885-0269
